Ischemia/reperfusion (I/R) injury following stroke can worsen patient outcome through excess inflammation. This study investigated the pharmacologic potential of targeting an endogenous anti-inflammatory circuit via formyl peptide receptor (FPR) 2/lipoxin receptor (ALX) (Fpr2/3 in mouse) in global cerebral I/R. Mice (C57BL/6 and Fpr2/3 2/2 ) were subjected to bilateral common carotid artery occlusion, followed by reperfusion and treatment with FPR agonists: AnxA1 [Annexin A1 mimetic peptide (Ac-AMVSEFLKQAWFI-ENEEQEYVQTVK), 2.5 mg/kg] and 15-epimer-lipoxin A4 (15-epi-LXA 4 ; FPR2/ALX specific, 12.5 and 100 ng/kg). Leukocyte-endothelial (L-E) interactions in the cerebral microvasculature were then quantified in vivo using intravital fluorescence microscopy. 15-epi-LXA 4 administration at the start of reperfusion reduced L-E interactions after 40 min (which was sustained at 2 h with high-dose 15-epi-LXA 4 ) to levels seen in sham-operated animals. Anx-A1 Ac2-26 treatment decreased leukocyte adhesion at 40 min and all L-E interactions at 2 h (up to 95%). Combined treatment with AnxA1 Ac2-26 plus FPR antagonists t-Boc-FLFLF (250 ng/kg) or WRW4 (FPR2/ALX selective, 1.4 mg/kg) abrogated the effects of AnxA1 Ac2-26 fully at 40 min. Antagonists were less effective at 2 h, which we demonstrate is likely because of their impact on early L-E interactions. Our findings indicate that FPR2/ALX activity elicits considerable control over vascular inflammatory responses during cerebral I/R and, therefore, provide evidence that targeting
FOLLOWING ISCHEMIC STROKE, ischemia/reperfusion (I/R) injury may elicit excessive inflammation that compounds brain damage considerably. Early in I/R, microglia become activated, releasing inflammatory cytokines into the injured brain (1) . Leukocytes interact with cerebral microvascular endothelia according to chemokine and cell adhesion molecule (CAM) expression and eventually emigrate into injured tissue, where they release highly reactive components. The inflammatory response must therefore be efficiently modulated to prevent further brain damage.
Leukocyte recruitment during experimental I/R is associated with tissue damage in stroke (subsequent to an initial ischemic insult) and provides the premise for therapeutic disruption of leukocyte-endothelial (L-E) interactions: neuroprotection and improved behavioral outcome have been demonstrated following experimental stroke with adhesion molecule-specific monoclonal antibodies (2, 3) , as well as in adhesion molecule-deficient animals (4) (5) (6) . None of these promising preclinical results, however, has translated into an effective therapy, necessitating an alternative route to anti-inflammation, which is investigated here.
The resolution of inflammation involves active processes rather than passive dissolution, and recent promising results have emerged from enhancement of these mechanisms in the heart and other tissues (7, 8) . Endogenous contingency plans triggered by excess inflammation are mediated in part by eicosanoid-derived lipoxin A4 (LXA 4 ) and Annexin A1 (AnxA1) [pharmacophore AnxA1 (Annexin A1 mimetic peptide (Ac-AMVSEFLKQAWFIE-NEEQEYVQTVK)), an N-terminal peptide of the fulllength protein], a glucocorticoid-induced 37 kDa calcium and phospholipid-binding protein, respectively. Both LXA 4 and AnxA1 are able to exert effects through a common GPCR: formyl peptide receptor (FPR) 2/the lipoxin receptor (ALX) (mouse ortholog Fpr2/3) (9, 10) . FPR2/ALX is a member of the FPR family that exists predominantly on cells of myeloid lineage, including neutrophils, which are heavily involved in acute-phase inflammation observed in the early stages of reperfusion following stroke (11) . FPR2/ALX activity produces cell-/ agonist-specific responses to inflammatory stimuli-it is a pluripotent receptor therefore that may elicit either pro-or anti-inflammatory responses depending on the binding of specific ligands and also as a result of homo-/heterodimer formation with other members of the FPR family (FPR1 and FPR3) (12) . In general, however, FPR2/ALX acts to resolve inflammation through several mechanisms, including promotion of nonphlogistic apoptosis and phagocytosis of leukocytes within tissue, CAM shedding, and the release of anti-inflammatory cytokines. Here, we study cerebral inflammation following global stroke in mice, as a model of cerebral I/R elicited through atherosclerotic degeneration of the common carotid arteries (CCAs), or respiratory/cardiac arrest in humans. We use intravital microscopy (IVM) to visualize L-E interactions and demonstrate that targeting FPR2/ALX is able to modulate the vascular inflammatory responses associated with I/R injury, in a dose-and time-dependent fashion. Therefore, these data suggest that FPR2/ALX is a potential antiinflammatory therapeutic target.
MATERIALS AND METHODS

Animal preparations
Experiments were performed using male C57BL/6 mice (Charles River Limited, Margate, Kent, United Kingdom) or male Fpr2/3 2/2 mice backcrossed for 6 generations on a C57BL/6 background (13), weighing 23-28 g. All animal procedures were carried out under license and complied with home office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986). Mice were maintained on a 12 h light-dark cycle during which room temperature was maintained at 21-23°C, and had access to a standard chow pellet diet and tap water ad libitum. Animals were anesthetized with an intraperitoneal injection of pentobarbital sodium (100 mg/kg; Merial, Essex, United Kingdom), as used elsewhere for induction of long-lasting anesthesia in murine stroke (14, 15) . The right jugular vein was cannulated with a PE-10 catheter for intravenous administration of saline, treatments, and dye. Body temperature was monitored throughout using a rectal thermometer and maintained at 37 6 0.5°C using a heating mat on which all surgery was performed.
Bilateral common carotid artery occlusion and treatments
Animals underwent bilateral common carotid artery occlusion (BCCAO) followed by reperfusion for up to 3 h (16). In brief, both CCAs were exposed via a ventral midline incision at the level of the neck. In ischemic groups, CCAs were clamped using aneurysm clips (Fine Science Tools, Cambridge, United Kingdom) for 5 min (17) . The clips were then removed, and resumption of blood flow was confirmed visually. At the start of reperfusion, mice were administered vehicle intravenously (saline or ethanol plus saline; 100 ml) or treatment in 100 ml vehicle: AnxA1 Ac2-26 (100 mg); 15-epimer-lipoxin A 4 (15-epi-LXA 4 ) (stable epimer of LXA 4 , see Fig. 1 ; 0.5 or 4.0 mg); WRW4 (55 mg); Boc2 (t-Boc-FLFLF; 10 mg); AnxA1 Ac2-26 plus Boc2; or Ac2-26 plus WRW4. In shamoperated animals, the CCAs were exposed but not clamped (n = 4-7 mice per group for all treatments.) Where pretreatments were used, minocycline (90 mg/kg) in DMSO plus saline or vehicle was administered intraperitoneally 1 h before BCCAO.
Cranial window
Each mouse was set on a stereotactic frame in a sphinx position. The left parietal bone was exposed, and a circular craniotomy was performed (diameter, 2-3 mm; centered ;3 mm from the coronal and sagittal sutures) with dura left intact. Viewing L-E interactions using intravital fluorescence microscopy At 5 min before IVM, mice were administered 100 ml rhodamine 6G (0.02% in saline; Sigma-Aldrich); intravenous rhodamine 6G is a fluorescent dye that is selectively absorbed by leukocytes and is used regularly to visualize leukocytes in vivo using fluorescence (18, 19 (continued from previous page) Fl in , fluorescence intensity inside; Fl out , fluorescence intensity outside; FPR, formyl peptide receptor; I/R, ischemia/reperfusion; IVM, intravital microscopy; L-E, leukocyte-endothelial; LXA 4 , lipoxin A 4 ; TRITC, tetramethylrhodamine isothiocyanate
Video analysis
There were 3 to 5 randomly selected postcapillary venular segments, 30-70 mm in diameter and with at least 100 mm of observable length, plus 1 arteriole (in which L-E interactions were never seen), filmed over 2 min for each mouse. Vessels in which blood flow was affected by the "no-reflow" phenomenon (20, 21) were disregarded so that slow leukocyte movement could be attributed to increased inflammation rather than reduced forward momentum on leukocytes. The number of rolling leukocytes (millimeter squared), rolling velocity of these leukocytes (micrometer per second), and the number of adherent leukocytes (millimeter squared) were assessed. Rolling leukocytes were defined as cells crossing a designated boundary within the 100 mm vessel length at a velocity discernibly slower than the central flow. (Cells traveling at general flow rate are indistinguishable due to their velocity.) Adherent cells were defined as those remaining stationary within the vessel for #30 s. Counts were expressed as square millimeters of venular surface (over the analyzed 2 min), as interpreted from vessel diameter and assuming a cylindric shape.
Plasma extravasation
Plasma extravasation in the postcapillary venules was measured using tetramethylrhodamine isothiocyanate (TRITC)-dextran (0.25 mg in 5 ml vehicle per gram body weight i.v.; Sigma-Aldrich). There were 3 to 5 snapshots of vessels taken for each mouse. Images were obtained using block filter (excitation, 547 nm; emission, 572 nm). Albumin leakage was quantified by measuring mean fluorescence intensity inside (Fl in ) and outside (Fl out ) the venule normalized for background fluorescence (i.e., area of no leakage), using image analysis software (ImageJ; NIH, Bethesda, MD, USA): albumin leakage = [(Fl out 2 baseline)/(Fl in 2 baseline)] 3 100%.
Blood and tissue collection
Blood was taken by cardiac puncture into a heparinized syringe. Blood was centrifuged at 4°C, 10,000 rpm for 5 min to yield the plasma then stored at 280°C until required. For histologic samples, mice were perfused transcardially with saline followed by 4% paraformaldehyde/0.5% glutaraldehyde. After 24 h, brains were removed and transferred to 10% [4% paraformaldehyde/0.5% glutaraldehyde] until required.
Immunohistochemistry
Fixed brains (see above) were washed in tap water, dehydrated in an ethanol series, and embedded in paraffin. Quantitative analysis of microglia was performed on 4 mm sections of samples that were immunostained with Iba-1. After antigen retrieval using citrate buffer (pH 6.0) at 96°C for 30 min, the endogenous peroxide activity was blocked, and the sections were incubated overnight at 4°C with the primary rabbit polyclonal anti-Iba1 (1: 1000; Wako, Los Angeles, CA, USA) diluted in 1% bovine serum albumin. After washing, sections were incubated with a secondary biotinylated antibody (Dako, Cambridge, United Kingdom). Positive staining was detected using a peroxidase-conjugated streptavidin complex and color developed using 3,39-diaminobenzidine substrate (Dako, Cambridge, United Kingdom). The sections were counterstained with hematoxylin. Cell counts were evaluated in tissue sections by visual inspection in a blind fashion and counted with a high-power objective (403) on an Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss, Jena, Germany). There were 27 randomly selected fields within the brain sections analyzed, per animal, and the area was determined with the AxioVision software (Carl Zeiss). Values were reported as the number of cells per square millimeter. Figure 2 . Global cerebral I/R increases L-E interactions in the cerebral microvasculature of C57BL/6 mice. Animals were subjected to BCCAO for 5 min followed by either 40 min or 2 h of reperfusion. In sham-operated animals (0 min of ischemia), CCAs were exposed but not occluded. Representative images of cellular changes in postcapillary venules of the pial microcirculation show minimal leukocyte (white arrows) interaction in sham groups (A) and increased leukocyte rolling and adherence following I/R (5 min of ischemia/40 min of reperfusion), as observed using IVM (B-E). (A) and (B) are still images taken from a video over 9 s to illustrate leukocyte rolling (blue/green circles) and adhesion (orange circles). Leukocytes are visible as red dots due to uptake of rhodamine 6G, and the surrounding lumen is visible through autofluorescence (peripheral features are not visible due to the dense nature of the tissue). After 40 min/2 h, L-E interactions were analyzed over 2 min: the number of rolling leukocytes (C), rolling cell velocity (D), and number of adherent leukocytes (E) were counted over a 100 mm vessel, and rolling and adherent cells are expressed as number per square millimeter. Data are the mean 6 SEM and assessed by ANOVA followed by Bonferroni (n = 4-6 miceper group). P,0.05vs.*shamor
Quantitative analysis of extravasated neutrophils was performed on 4 mm sections of brain tissue stained with hematoxylin and eosin, using a high-power objective (363) on an Axioskop 2-Mot Plus Zeiss microscope. There were 7 random fields in the brain tissues analyzed per animal (n = 5 mice per group), and the area was determined using AxioVision software. Values are expressed as the mean 6 SEM of the number of cells per square millimeter.
Statistical analysis
All values are expressed as the mean 6 SEM for all animals in each treatment group (n). Statistical significance was assessed by ANOVA followed by Bonferroni. In all cases, P , 0.05 was considered significant.
RESULTS
BCCAO plus reperfusion (I/R) increases L-E cell interactions
Five-minute global ischemia followed by 40 min or 2 h of reperfusion in C57BL/6 mice was associated with a significant increase in the number of rolling and adherent leukocytes in postcapillary venules ( Fig. 2C-E ; P , 0.05; n = 4-7 mice per group) when compared to sham controls (adherent cells per square millimeter, 315.4 6 37.3 at 40 min and 610.7 6 102.3 at 2 h in I/R groups versus 59.3 6 20.2 and 40.7 6 13.1 in the sham group). Figure 2A , B shows representative images of these L-E interactions. At 2 h, leukocyte adhesion was further exacerbated above that observed at the 40 min time point (Fig. 2E) . Leukocyte rolling velocity was reduced at 2 h (P , 0.05) but not 40 min in animals that had undergone I/R.
The blood-brain barrier (BBB) plays a pivotal role in the healthy and diseased CNS and contributes to increased mortality after ischemic stroke. Postcapillary venule leakage was assessed using TRITC-labeled dextran to assess BBB integrity (22) . Little difference was observed between the sham and I/R groups, indicating preservation of BBB integrity at 40 min and 2 h time points observed (Supplemental Fig. 1 ). This was not the case post 2 h and was associated with a higher mortality rate (Fig. 7) .
Pretreatment with minocycline indicates a microglial mechanism for increased L-E interactions following I/R
Having observed the effects of cerebral I/R on L-E interactions, the role of resident microglial cells (which express Fpr2/3) was assessed. The number of activated microglial Figure 3 . Microglial inhibition prevents increases in L-E interactions in cerebral I/R-induced inflammation. Animals were subjected to (A) sham or (B) BCCAO for 5 min followed by 2 h of reperfusion, and brain sections were immunostained with antiIba1 (1:1000) to detect activated microglia (arrows). Veh, vehicle. Scale bars, 10 mm. C) Quantitative analysis of microglia in the brain. 15-epi, 15-epi-LXA 4 . Data represent the mean 6 SEM of the total number of activated microglia per square millimeter observed in 27 fields analyzed per animal. Data are assessed by ANOVA followed by Bonferroni (n = 4 mice per group). *P , 0.05 vs. sham group; ###P , 0.05 vs. vehicle 1 group; #P , 0.05 vs. vehicle 2 group. Microglial activity was inhibited using pretreatment with minocycline (90 mg/kg, 1 h prior to BCCAO) or vehicle (saline/DMSO). BCCAO was carried out for 5 min. A shamoperated group (no I/R) was included. After 2 h of reperfusion, L-E interactions were analyzed over 2 min: the number of rolling leukocytes (D), rolling cell velocity (E), and number of adherent leukocytes (F) were counted over a 100 mm vessel, and rolling and adherent cells are expressed as number per square millimeter. Data are the mean 6 SEM and assessed by ANOVA followed by Bonferroni (n = 4-6 mice per group). *P , 0.05 vs. sham, or Student's t test, # P , 0.05 vs. vehicle.
cells was increased following I/R (Fig. 2B, C) . In addition, after the activity of resident microglia was inhibited using pretreatment with minocycline (23) (90 mg/kg, 1 h before BCCAO), the number of rolling and adherent cells was reduced (and rolling velocity increased) significantly versus vehicle treatment groups (P , 0.05; n = 4 mice per group; Fig. 3D-F) . Indeed, no adherent cells were observed in any animal in the minocycline group (adherent square millimeters, 124.7 6 24.9 vs. 0.0). It should be noted, however, that adhesion levels were lower across both pretreatment groups (including vehicle) than in groups receiving no pretreatment (Fig. 3 vs. Fig. 2 ) and, conversely, that the number of rolling cells in pretreated animals was higher than those without pretreatment.
FPR agonist AnxA1 Ac2-26 protects against I/R Initial studies examined whether or not FPR ligand Anx-A1 Ac2-26 retained its cerebroprotective properties in the mouse model of cerebral I/R described above. The peptide (100 mg, 100 ml saline/mouse) reduced associated inflammation when administered at the start of reperfusion. At 40 min of reperfusion, there were significantly fewer adherent cells versus vehicle groups (P , 0.05; adherent cells per square millimeter, 80.0 6 44.7 versus 315.4 6 37.3 adherent cells per square millimeter; Fig. 4C ), although neither the number of rolling cells nor rolling velocity was significantly altered. At 2 h of reperfusion, not only did treatment with AnxA1 Ac2-26 maintain significantly reduced adhesion, but it also increased the velocity at which the leukocytes were traveling to sham levels (Fig. 4B) . No significant changes in the number of rolling cells were observed at either time point. At 2 h, AnxA1 Ac2-26 also reduced the number of activated microglial cells (Fig. 3C) . The role of Fpr(s) in the protection produced by AnxA1 Ac2-26 was then determined by cotreatment with panFpr and Fpr2/3-selective antagonists. Treatment with panFpr antagonist Boc2 prevented the antiadhesive effect of AnxA1 Ac2-26 (P , 0.05; Fig. 4 ). This effect was replicated when the more specific antagonist to FPR2/ALX (the human ortholog for Fpr2/3), WRW4, was administered (Fig. 4C) , suggesting an FPR (selectively Fpr2/3) mechanism at this 40 min time point.
As described in the previous paragraph, both Boc2 and WRW4 blocked the antiadhesive properties seen with AnxA1 Ac2-26 , suggesting an Fpr2/3 protective mechanism at 40 min of reperfusion. Unexpectedly, at this time point, Boc2 and WRW4 groups (both when either antagonist was used alone or in conjunction with AnxA1 Ac2-26 ) in fact produced inverse agonistic effects in the microvasculature. There was a marked increase (up to 5-fold) in the number of rolling cells at 40 min in these groups versus vehicle groups as well as sham groups (P , 0.05; Fig. 4A ). Unlike Boc2 alone, treatment with WRW4 alone produced greater levels of L-E interactions than AnxA1 Ac2-26 /WRW4 in combination as well as increased cell rolling velocity. At 2 h of reperfusion, the effects of treatment with either antagonist, both alone and in combination with AnxA1 Ac2-26 , were not as pronounced at 40 min (P , 0.05; Fig. 4) .
Large numbers of rolling cells in WRW4 (and Boc2) treatment groups at 40 min and reduced cell rolling and adhesion at 2 h versus vehicle groups led to the hypothesis that WRW4 may initiate more acute/profound inflammation in mice and that this was undergoing resolution at 2 h. To investigate this, cell activity was recorded in 9 mice A B C Figure 4 . FPR2/ALX-selective antagonist WRW4 and FPR panantagonist Boc2 eliminate antiadhesive properties of AnxA1 Ac2-26 . After 5 min of BCCAO, mice were administered intravenous vehicle (100 ml saline/mouse), AnxA1 Ac2-26 (100 mg/mouse), WRW4 (55 mg/mouse), Boc2 (10 mg/mouse), or AnxA1 Ac2-26 plus WRW4/Boc2 at the start of reperfusion. A sham-operated group (no I/R) was included. After 40 min or 2 h of reperfusion, L-E interactions were analyzed over 2 min: the number of rolling leukocytes (A), rolling cell velocity (B), and number of adherent leukocytes (C) were counted over a 100 mm vessel, and rolling and adherent cells are expressed as number per square millimeter. Data are the mean 6 SEM and assessed by ANOVA followed by Bonferroni (n = 4-7 mice per group). *P , 0.05 vs. sham; # P , 0.05 vs. vehicle; u P , 0.05 vs. AnxA1 longitudinally between the 2 time points, and resulting data appeared to uphold this hypothesis. Fig. 5C ), and the final recorded adherence levels (105 # 120 min) significantly reduced versus the peak (P , 0.05; Fig. 5C ). Although the emigration of leukocytes cannot be studied using fluorescent IVM, brain sections (which had been perfused with PBS and fixed, eliminating the inclusion of intravascular cells) were stained using immunohistochemistry. Figure 6 clearly demonstrates the significant reductions in emigrated leukocytes following treatment with both 15-epi-LXA 4 and AnxA1 Ac2-26 , (P , 0.05 and P , 0.01, respectively).
15-epi-LXA4 indicates a role for FPR2/ALX in reducing inflammation in global cerebral I/R
To provide further evidence for the protective potential of targeting FPR2/ALX in stroke, experiments were conducted using FPR2/ALX-specific agonist 15-epi-LXA 4 and in Fpr2/3 2/2 mice (see next section for the latter). At 40 min of reperfusion, treatment of mice with 15-epi-LXA 4 (0.5 and 4.0 mg/mouse) reduced the inflammatory response associated with I/R (Fig. 7) . Both the number of rolling cells and the number of adherent leukocytes were significantly reduced to levels comparable with those seen in sham-operated animals (P , 0.05). In addition, cell rolling velocity was significantly increased compared with vehicle-treated mice (P , 0.05).
At 2 h of reperfusion, only the higher-dose 15-epi-LXA 4 (4.0 mg/mouse) was able to sustain anti-inflammatory effects seen at 40 min of reperfusion. In these animals, the numbers of rolling and adherent leukocytes were significantly reduced at 2 h (P , 0.05; Fig. 7 ), as were the number of activated microglial cells (Fig. 3C) . Table 1 shows the levels of TNF, MCP-1, IL-6, and IL-10 in plasma samples of mice subjected to the different treatment groups. Interestingly, 15-epi-LXA 4 increased both MCP-1 and IL-6 levels at 2 h (P , 0.05).
Physiologic role of Fpr2/3 in inflammation
To study the physiologic role of Fpr2/3 in global stroke, Fpr2/3 2/2 mice were subjected to 5 min of BCCAO followed by 40 min and 2 h of reperfusion. Fpr2/3 2/2 mice showed no significant increase in inflammation versus sham groups; in fact, the Fpr2/3 2/2 groups had cell adhesion levels significantly lower than C57BL/6 groups (P , 0.05; Fig. 8 ). This seemed somewhat strange given the above data that demonstrate a role for Fpr2/3 in global I/R. To investigate this unexpected response, the reperfusion period was extended to 3 h in both Fpr2/3 2/2 and C57BL/6 mice. Not one of the Fpr2/3 2/2 mice survived for the full 3 h, whereas 40% C57BL/6 mice survived. The trend for better survival in C57BL/6 mice is seen also at 40 min and 2 h of reperfusion: only 20% of the null mice could be observed at 2 h (vs. 65% C57BL/6 mice). Therefore, our observable data may be skewed in favor of less inflammation in the former group because higher mortality is associated with greater levels of inflammation. In contrast to the mortality rates seen in the Fpr2/3 2/2 mice, 100% of mice survived up to 3 h following treatment with either AnxA1 Ac2-26 or 15-epi-LXA 4 . Figure 7 . 15-epi-LXA 4 inhibits L-E interactions in cerebral I/R-induced inflammation. After 5 min of BCCAO, mice were administered intravenous vehicle (100 ml saline plus ethanol per mouse) or 15-epi-LXA 4 (0.5 or 4.0 mg/mouse) at the start of reperfusion. A sham-operated group (no I/R) was included. After 40 min or 2 h, L-E interactions were analyzed over 2 min: the number of rolling leukocytes (A), rolling cell velocity (B), and number of adherent leukocytes (C) were counted over a 100 mm vessel, and rolling and adherent cells are expressed as number per square millimeter. Data are the mean 6 SEM and assessed by ANOVA followed by Bonferroni (n = 4-6 mice per group). *P , 0.05 vs. sham; # P , 0.05 vs. vehicle.
DISCUSSION
Associations between the damaging effects of inflammation and noninfectious diseases are continually being drawn, in which alternative stressful stimuli provoke a response intended to tackle pathogens. We investigated inflammation in a mouse model of global cerebral I/R and attempted to modulate this inflammation through FPR2/ ALX (mouse ortholog Fpr2/3) activity. In doing so, we contribute to evidence that anti-inflammatory treatment through this mechanism could be beneficial in ischemic stroke.
Our experimental global model of cerebral I/R represents human stroke conditions caused by atherosclerotic degeneration of the CCAs, respiratory arrest, and cardiac arrest. Our model involved 5 min global cerebral ischemia in C57BL/6 mice, following which L-E interactions were assessed using IVM at 2 time points during blood reperfusion into the brain (40 min and 2 h). Differences in L-E interactions at each stage are likely to be due to temporal expression of CAMs such as P-selectin and intercellular adhesion molecule 1 (6, 24) . Where IVM has previously been used, an ischemic period of 1 h plus 40 min of reperfusion had caused neuronal tissue damage commensurate with a significant inflammatory response (25, 26) . Other groups have shown, however, that damage occurs after as few as 5 (16) and 3 (27) min of ischemia and that mortality rates in C57BL/6 mice reach 75 (16) to 80% (28) before 1 h of ischemia is induced through BCCAO-these were the premises for our shorter ischemic duration. This model produced an increase in L-E interactions up to 15-fold the magnitude of sham groups.
In accordance with previously published data (23, 29) , our model appears to be, at least in part, related to microglia activity. When microglia activity was inhibited by pretreatment with minocycline (which suppresses hypoxic activation of microglia), L-E interactions were reduced to levels observed in sham-operated animals. Increased levels of Iba-1 (indicative of activated microglia) were also detected in vehicle versus sham groups. Although minocycline is widely used as an inhibitor of microglial activity (30) (31) (32) , the second-generation tetracycline has also been shown to have anti-inflammatory, antioxidant, and antiapoptotic properties (33) . Therefore, whereas our minocycline pretreatment groups and immunostaining suggest a regulatory role for microglial in this model, an indirect inhibitory effect of minocycline on microglial activation cannot be excluded.
Treatments administered at the start of reperfusion provided evidence that FPR2/ALX could be targeted in order to modulate L-E interactions in cerebral I/R. Data sets from mice treated with AnxA1 Ac2-26 (an AnxA1 pharmacophore able to act through all members of the FPR family), combined AnxA1 Ac2-26 /antagonist (Boc2 or WRW4), or antagonist alone indicated an anti-inflammatory Fpr2/3 mechanism in this model of stroke.
We observed a reduction in L-E interactions (in adhesion only at 40 min, but in both rolling and adhesion to a remarkable level at 2 h) after treatment with peptide AnxA1 . It has been shown previously that glucocorticoid-induced AnxA1 is able to cause leukocyte detachment from endothelia through shedding of L-selectin (a leukocyte-bound mediator of cell rolling) via FPR2/ALX (34, 35) . Indeed, because increased L-E 
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Blood was collected from sham mice or animals subjected to 5 min global ischemia followed by 40 min or 2 h of reperfusion. Some mice received vehicle 1 (V1; 100 ml saline/mouse), vehicle 2 (V2; 100 ml saline plus ethanol per mouse), AnxA1 interactions following antagonist treatments at 40 min are isolated to rolling cells, rather than adherent cells, the blocking of FPR2/ALX may lead to an increase in endogenous selectin activity and, hence, an increase in the number of rolling cells.
Several points are raised when AnxA1 Ac2-26 treatment is used in conjunction with FPR antagonists. The reduction of leukocyte rolling and adhesion at 40 min brought about by AnxA1 Ac2-26 was abrogated by combined treatment with either Boc2 or WRW4, which suggests an Fpr2/3 mechanism (shared with 15-epi-LXA 4 ) for AnxA1 Ac2-26 at this time point. At the later time point of 2 h, antiadhesive effects are abrogated by only 20% (compared with 100% at 40 min). Independently, data from the 2 h time point suggest that AnxA1 Ac2-26 is acting via an additional alternative mechanism at 2 h. However, stability and potency of compounds over the 40 min versus 2 h period must be considered, particularly because both Boc2 and WRW4 treatment (without AnxA1 Ac2-26 ) give rise to fewer adhesive leukocytes than the vehicle treatment group at 2 h. As with any finite inflammatory stimulus, it is possible that 5 min of ischemia is enough to produce a limited level of inflammation (i.e., an acute response) before endogenous resolution is instigated and that where Fpr2/3 antagonist treatment is given, activity is driven to reach this limit sooner. This is supported by longitudinal data obtained from mice observed between 40 min and 2 h, following treatment with WRW4.
We further indicate the potential of targeting FPR2/ ALX in stroke through the use of 15-epi-LXA 4 . 15-epi-LXA 4 is an LXA 4 epimer, which has an increased metabolic stability in comparison to its parent compound, LXA 4 (36) ; it is an anti-inflammatory eicosanoid and well characterized as a ligand for FPR2/ALX. Previous work shows cardioprotection following intravenous doses of 15-epi-16-(parafluoro)-phenoxy LXA 4 methyl ester (another stable LXA 4 analog) at 2-4 mg/mouse in a C57BL/6 mouse model of myocardial infarction (37) . We observed striking anti-inflammation (75% reduction) 40 min into reperfusion with just 0.5 mg 15-epi-LXA 4 (which was replicated using an 8-fold increase in this dose). At 2 h of reperfusion, significant anti-inflammatory effects were seen in the higher-dose (4.0 mg) group only. LXA 4 is endogenously active in a paracrine or autocrine manner. It is typically formed through the passage of precursor molecules from one cell to the next through "transcellular Figure 8 . Absence of Fpr2/3 is associated with higher mortality. After 5 min of BCCAO, mice were administered intravenous vehicle (100 ml saline/mouse), AnxA1 Ac2-26 (100 mg/mouse), or 15-epi-LXA 4 (4.0 mg/mouse) at the start of reperfusion. A shamoperated group (no I/R) was included. After 40 min or 2 h of reperfusion, L-E interactions were analyzed over 2 min: the number of rolling leukocytes (A), rolling cell velocity (B), and number of adherent leukocytes (C) were counted over a 100 mm vessel, and rolling and adherent cells are expressed as number per square millimeter. D) Survival rate of Fpr2/3 2/2 mice vs. C57BL/6 mice up to 3 h of reperfusion was obtained (survival was 100% in sham groups). Data are the mean 6 SEM and assessed by ANOVA followed by Bonferroni (n = 4-7 mice per group). *P , 0.05 vs. sham; # P , 0.05 vs. C57BL/6.
biosynthesis," when platelets, neutrophils, and endothelia interact during inflammation (38) [although data show that macrophages are able to produce the lipid mediator independently (39, 40) ]. The short half-life of LXA 4 and its analogs relative to other substances (41, 42) indicates that sustained reduction in L-E interactions following higher doses of 15-epi-LXA 4 may trigger downstream activity, which itself perpetuates anti-inflammatory activity.
In addition to pharmacologic antagonism, which produced a ,5-fold increase in L-E interactions, Fpr2/3 2/2 mice were used to characterize a role for Fpr2/3. Where Fpr2/3 2/2 mice have been used previously, they have been described as "viable, fertile, and (as showing) no obvious developmental or behavioural defects" and have demonstrated considerably increased susceptibility to inflammation versus wild-type controls (13) . In this study, however, Fpr2/3 2/2 groups produced no L-E interactions significantly above sham groups. These results are likely due to the high mortality rates seen in Fpr2/3 2/2 mice at later stages of reperfusion, meaning that L-E interactions could only be recorded in those mice that survived (i.e., those with fatal levels of inflammation were inevitably excluded for the study). Indeed, previous studies have excluded ;20% of C57BL/6 mice from research using the BCCAO method due to patent posterior communicating arteries that prevent them from being significantly affected by the stroke (43) . Interestingly, Bena et al. (44) also found that a significant portion (;50%) of their Fpr2/3 2/2 mice also did not survive myocardial I/R injury (25 min of ischemia, followed by up to 90 min of reperfusion). In addition, in our data, 100% of mice (n = 3) following treatment with either 15-epi-LXA 4 or AnxA1 Ac2-26 survived to the end of the experiment (up to 3 h). This indicates an important role for Fpr2/3 in survival following I/R.
Cytokine levels are notoriously poor indicators of the levels of inflammation occurring in any given model, due to the temporal variability in their expression. It is part of the reason why the search for a reliable biomarker for stroke has so far, unfortunately, remained elusive. However, the attraction of monocytes (45) to an area (through MCP-1) is necessary for resolution. In addition, there is evidence that IL-6 increases IL-10 production, an established anti-inflammatory protein (46, 47) . The effects of both cytokines in these circumstances would be considered anti-inflammatory and may help to explain why both MCP-1 and IL-6 are elevated following 15-epi-LXA 4 treatment.
Mounting evidence demonstrates the protective effects of modulating inflammation in experimental models of sterile afflictions (8, 48, 49) . Our data suggest that targeting FPR2/ALX may be effective in reducing I/R injury following stroke. The variation in L-E interactions between agonist treatments and doses used, and between time points observed, raises appropriate questions regarding how anti-inflammatory treatments might be used in the clinic-which dose to use, when to administer, and perhaps how frequently-for optimal results. Overall, these data indicate the significance of Fpr2/3 in a model of global cerebral I/R and that modulation of human FPR2/ALX could produce significant protective effects in clinical stroke.
